NCT04048564 is a clinical trial in Chronic Myeloid Leukemia, sponsored by Incyte BioSciences France.

Who is sponsoring NCT04048564?

NCT04048564 is sponsored by Incyte BioSciences France.

What condition does NCT04048564 study?

NCT04048564 studies Chronic Myeloid Leukemia.

Is NCT04048564 still recruiting?

NCT04048564 is currently completed. Last updated 28 September 2023.

Last reviewed 2023-09-28 · How we verify

NCT04048564

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)

Completed Last updated 28 September 2023

What this trial tests

trial in Chronic Myeloid Leukemia in 120 participants. Completed in 3 July 2023.

Timeline

23 February 2018

Primary endpoint
31 December 2022

3 July 2023

Quick facts

Lead sponsor	Incyte BioSciences France
Status	Completed
Study type	OBSERVATIONAL
Enrollment	120
Start date	23 February 2018
Primary completion	31 December 2022
Estimated completion	3 July 2023
Sites	40 locations across France

Conditions studied

Chronic Myeloid Leukemia — all drugs for Chronic Myeloid Leukemia →

Sponsor

Incyte BioSciences France

Who can join

18 and older, any sex, with Chronic Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicentre ambispective cohort study involving French patients who have started or are receiving for less than 6 months a treatment with ponatinib. This study aims at better qualifying the ponatinib benefit-risk balance in real life and in relation with CML patients' therapeutic history.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in targeted therapy for acute myeloid leukemia.
Yu J, Jiang PYZ, Sun H, Zhang X, et al · · 2020 · cited 48× · PMID 32477567 · DOI 10.1186/s40364-020-00196-2
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
Huguet F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, et al · · 2024 · cited 3× · PMID 39506529 · DOI 10.1111/bjh.19819

Verify or expand the search:

Other recruiting trials for Chronic Myeloid Leukemia

Currently open trials in the same condition.

NCT06817720 — Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chroni · Phase 2 · recruiting
NCT07238712 — Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies · Phase 2 · recruiting
NCT06453902 — TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients · Phase 2 · recruiting
NCT06390306 — The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP · recruiting
NCT06355583 — Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04048564 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte BioSciences France
Last refreshed: 28 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04048564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing